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ABSTRACT 
KIBRA, a multi-functional scaffold protein 
with around twenty known binding partners, is 
involved in memory and cognition, organ size 
control via the Hippo pathway, cell polarity, and 
membrane trafficking. KIBRA includes tandem 
N-terminal WW domains, a C2 domain and 
motifs for binding aPKC and PDZ domains. A 
naturally occurring human KIBRA variant 
involving residue changes at positions 734 (M-to-
I) and 735 (S-to-A) within the C2 domain affects 
cognitive performance. We have elucidated 3D 
structures, and calcium and phosphoinositide 
binding properties, of human KIBRA C2 
domain. Both wild type and variant C2 adopt a 
canonical type I topology C2 domain fold. 
Neither Ca2+ nor any other metal ion was bound 
to wild type or variant KIBRA C2 in crystal 
structures, and Ca2+ titration produced no 
significant reproducible changes in NMR 
spectra. NMR and X-ray diffraction data indicate 
that KIBRA C2 binds phosphoinositides via an 
atypical site involving b-strands 5, 2, 1, and 8. 
Molecular dynamics simulations indicate that 
KIBRA C2 interacts with membranes via 
primary and secondary sites on the same domain 
face as the experimentally identified 
phosphoinositide binding site. Our results 
indicate that KIBRA C2 domain association with 
membranes is calcium-independent and involves 
distinctive C2 domain-membrane relative 
orientations. 
 
 
KIdney- and BRAin-expressed protein 
(KIBRA, also called WWC1 for WW- and C2-
domain-containing protein 1)1 is a large (1119, 1118 
and 1113 amino acid isoforms), multi-functional 
scaffold protein that has two N-terminal WW 
domains, a putative nuclear localization signal 
																																																								
1	The abbreviations used are: AD, Alzheimer’s 
disease; AMPAR, a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors; 
AUC, analytical ultracentrifugation; CBR, 
calcium binding region; ENM, elastic network 
model; KIBRA, KIdney- and BRAin-expressed 
protein; MD, molecular dynamics; C2(C771A), 
C771A mutant of KIBRA C2 domain; NLS, 
nuclear localization signal; NMR, nuclear 
magnetic resonance; NOE, nuclear Overhauser 
effect; PI(3)P,  phosphatidylinositol 3-
(NLS) (1), putative coiled coil regions, a C2 domain, 
a glutamic acid-rich motif, an atypical PKC (aPKC) 
binding region, and a C-terminal PDZ binding motif 
(Fig. 1). KIBRA has about twenty reported binding 
partners (2) and disease links including dementia (3-
5), kidney disease (6), Tourette disorder (7), and 
some cancers (8, 9). Among its multiple functions, 
KIBRA is an upstream component of the Hippo 
pathway (8, 10), a central mechanism of organ size 
control and cellular homeostasis. KIBRA also has a 
role in cell polarity and migration, functioning as a 
link between polarity proteins and cytoskeleton 
components (2, 11-14). KIBRA also functions in 
membrane trafficking via regulation of vesicular 
transport (12, 15-17).  
KIBRA is linked to memory, cognition, and 
neurological disorders in humans and in rodent 
models (reviewed in (2)). A single nucleotide 
polymorphism (SNP), rs17070145, in the ninth 
intron of KIBRA, for example, has been implicated 
in human cognition (15), a finding corroborated by 
numerous subsequent studies, including a meta-
analysis (16). Rs17070145 is associated with 
AlzheimerÕs disease (AD) (3, 17). KIBRA, 
moreover, has additive and epistatic interactions 
with APOE (18), the e4 allele of which is the 
strongest genetic risk factor for sporadic AD. The 
effect of SNP rs17070145 on memory and AD may 
arise due to differential activation of the MAPK 
pathway (19), important for memory and learning 
processes. In human, rat and mouse brains, KIBRA 
is mainly expressed in memory-related regions, 
including hippocampus and cortex, as well as 
cerebellum and hypothalamus (15, 20, 21).  
phosphate; PI(4,5)P2, phosphatidylinositol 4,5 
bisphosphate;  PI(3,4,5)P3, phosphatidylinositol 
3,4,5 trisphosphate; PME, particle mesh Ewald; 
RMSD, root mean square deviation; SNP, single 
nucleotide polymorphism;  varC2,  naturally 
occurring variant (M734I, S735A) KIBRA C2 
domain; varC2(C771A), C771A mutant of 
variant KIBRA C2 domain; wtC2, wild type 
KIBRA C2 domain; WWC, WW- and C2-domain-
containing protein; XRC, X-ray crystallography	
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KIBRA acts in the same pathway as protein 
kinase Mζ (PKMζ), a brain-specific kinase thought 
to be involved in long term memory storage through 
its control of neuroreceptor trafficking, particularly 
trafficking of ! -amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs), the 
major excitatory neurotransmitter receptors in the 
brain (22). KIBRA binds, co-localises with and is 
phosphorylated by PKMζ (11, 23), and KIBRA is 
involved in AMPAR trafficking (24). KIBRA 
counteracts proteasomal degradation of PKMζ (25). 
In addition, KIBRA binds to dendrin (26) and 
synaptopodin (13, 27), postsynaptic cytoskeleton 
organisers important for synaptic transmission and 
cognition. Aberrant acetylation of tau, linked to 
cognitive deterioration in dementia, disrupts 
postsynaptic function by reducing postsynaptic 
KIBRA (4, 28). Consistent with these accumulated 
observations, KIBRA overexpression and 
knockdown exert positive and negative effects 
respectively on key molecular and cellular processes 
in neurons (29). It has been shown by 
immunoprecipitation that KIBRA can form 
homodimers (20) and heterodimers with the two 
other WWC protein family members, WWC2 and 
WWC3 (10), although the functional significance of 
this remains unknown. 
Here we characterize the calcium and 
phosphoinositide binding properties of KIBRA C2 
domain (Fig. 1), including a variant that arises from 
two SNPs (rs3822660G/T and rs3822659T/G) in 
human KIBRA that result in substitution of two 
adjacent residues (M734I, S735A) (30). Although 
the molecular consequences of these exonic SNPs 
have not been fully elucidated, they affect cognitive 
performance and there is almost complete linkage 
disequilibrium between the aforementioned intronic 
SNP rs17070145 (15) and rs3822660G/T and 
rs3822659T/G (30).  
The C2 domain is found in more than 125 
different human proteins (31, 32). Whilst most C2 
domains are Ca2+-dependent membrane association 
domains, some C2 domains do not bind Ca2+ and 
some mediate protein-protein rather than protein-
lipid interactions (31, 32). Our experimental and 
computational investigation of wild type and variant 
KIBRA C2 domains indicate that KIBRA C2 is a 
non-canonical C2 domain that in vitro both binds 
phosphoinositides and associates with membranes in 
an atypical, calcium-independent manner.  
 
Results 
Wild type and variant KIBRA C2 adopt a typical C2 
fold 
Our 2.6  resolution crystal structure (PDB 
6FD0) shows that varC2 adopts a typical eight-
stranded b-sandwich C2 domain fold. The crystal 
form comprises a parallel dimer (i.e. the two 
monomers are parallel to each other) formed via an 
inter-monomer disulfide bond involving C771, the 
fifth and only unpaired cysteine in KIBRA C2 (Fig. 
2A). The previously available crystal structure of 
wild type KIBRA C2 (PDB 2Z0U) involves a 
similar parallel, C771 disulfide-linked dimer.  
According to AUC measurements (SI Fig. 1, SI 
Table 2), wtC2 and varC2 samples both comprise a 
mixture of monomer and dimer in solution.  
On the other hand, AUC and NMR relaxation 
measurements (SI Figs. 1 and 2, SI Tables 2 and 3) 
indicate that the C2(C771A) and varC2(C771A) 
mutants are monomeric in solution. NMR samples 
of C2(C771A) and varC2(C771A) were 
homogeneous and stable, permitting backbone 
resonance assignments to be made using standard 
NMR methods (SI Fig. 3). Although AUC and NMR 
indicate that C2(C771A) is monomeric in solution, 
its crystal structure PDB 6FB4; 2.5  resolution) 
comprises an anti-parallel dimer (Fig. 2B), most 
likely formed due to crystal packing.  
The backbone 1H, 13C and 15N NMR chemical 
shifts of C2(C771A) and varC2(C771A) match 
closely the corresponding chemical shifts back-
calculated using Sparta (33) from the C2(C771A) 
crystal structure (PDB 6FB4). Correspondingly, the 
TALOS+ (34) and Sparta (33) predictions are that 
the secondary structure compositions of C2(C771A) 
and varC2(C771A) in solution are very similar to the 
C2(C771A) crystal structure (SI Fig. 4). The b-sheet 
NOE patterns of C2(C771A) and varC2(C771A), 
moreover, are as expected based on the C2 topology 
I fold, allowing for peak overlap and absence. NMR 
data therefore indicate that C2(C771A) and 
varC2(C771A) in solution are conformationally very 
similar to each other (SI Fig. 5) and to C2 monomers 
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in C2(C771A), varC2 (6FB4, 6FD0, respectively) 
and wtC2 (PDB 2Z0U) crystal structures. 
Since KIBRA dimerisation has been indicated 
by cell-based data (10, 20), MD simulations were 
conducted to compare conformational stabilities of 
the C2 dimers observed in crystal structures. Both 
parallel dimers (wtC2/2Z0U and varC2/6FD0) 
exhibited significant changes in relative monomer 
position (Fig. 3) with the changes varying between 
repeat simulations and force fields. In wtC2 dimer 
simulations the mean RMSD value after three repeat 
simulations was 0.52 ± 0.04 nm and 0.49 ± 0.05 nm 
for GROMOS and OPLS forcefields, respectively. 
The corresponding values in varC2 simulations were 
0.51 ± 0.08 nm and 1.4 ± 0.23 nm. In equivalent 
simulations, in contrast, the C2(C771A) anti-parallel 
dimer (PDB 6FB4) did not undergo significant 
changes in relative monomer position. There were 
no significant conformational changes within C2 
monomers in any simulation (Fig. 3).  
 
NMR and X-ray diffraction data indicate that 
KIBRA C2-Ca2+ interaction is very low affinity and 
non-specific 
Ca2+ binding was investigated by NMR, XRC 
and simulation. In numerous 1H-15N HSQC-
monitored titrations with C2(C771A), and one with 
wtC2, calcium chloride addition to 10-20 mM and 
sometimes higher concentration (up to 76 mM) 
produced no significant reproducible chemical shift 
change, with the largest composite 1H-15N changes 
around 0.05 ppm. Such small changes may be due to 
a very weak Ca2+ ion interaction (Kd > 10 mM), 
possibly non-specific Ca2+ binding to oxygen-rich 
surface clusters. Such a non-specific interaction is 
supported by simulation: when eight Ca2+ ions were 
initially positioned randomly around KIBRA C2, the 
final Ca2+ positions in eight simulations included the 
CBRs plus six other locations around the domain (SI 
Fig. 6).  
It is also possible that the domain scavenged 
Ca2+ during expression and purification and was 
therefore Ca2+-bound prior to the experiments, 
although this seems unlikely since particular effort 
was made during some C2 NMR sample 
preparations to exclude Ca2+. Initial 1H-15N HSQC 
spectra were very similar, furthermore, irrespective 
of whether or not measures were taken to exclude 
Ca2+ from NMR samples. 
In several crystal structures including wtC2 
(PDB 2Z0U), and our C2(C771A) and varC2 
structures, no bound Ca2+ has been observed, 
although the protein for 2Z0U was produced by cell 
free synthesis and the 2Z0U PDB entry does not 
mention any attempt to introduce metal ions. The 
crystal structures determined here used E. coli-
expressed protein with no attempt to exclude Ca2+, 
however, so the C2 domains presumably 
encountered Ca2+ and other divalent metal ions 
during expression and purification. Several times C2 
crystals were soaked in solutions containing divalent 
metal ions including 20 mM CaCl2, 100 mM CaCl2 
and 100 mM MnSO4. Soaking did not cause visible 
disintegration of the crystals. Diffraction after 
soaking was still good, but these experiments 
yielded only one metal-bound structure which had 
one Ca2+ located in the inter-monomer interface of a 
C2 dimer rather than in any of the CBRs.  
Overall, our NMR and XRC data are consistent 
with KIBRA C2 domain having very low (Kd > 10 
mM), non-specific affinity for Ca2+. Together with 
PDB entry 2Z0U, moreover, our NMR and XRC 
data show that lack of bound Ca2+ does not disrupt 
KIBRA C2 from adopting a typical C2 domain fold. 
 
KIBRA C2 exhibits an unusual phosphoinositide 
interaction mode  
NMR and XRC studies were conducted in order 
to define the phosphoinositide binding site 
location(s) on KIBRA C2. Three NMR titrations 
were conducted by recording 1H-15N HSQC spectra 
as a function of increasing concentration of 
phosphoinositide and subsequently calcium 
chloride. These titrations, involving C2(C771A) 
with PI(3)P, C2(C771A) with PI(4,5)P2, and varC2 
with PI(4,5)P2, produced very similar results in 
which phosphoinositide-induced chemical shift 
changes were observed for numerous peaks, almost 
all located in the b-sheet comprising b-strands 5, 2, 
1 and 8 (Fig. 4). L666 (b1), I677 (b2) and L678 (b2) 
backbone 1H-15N peaks exhibited the largest 
chemical shift perturbations with changes observed 
for around twenty further backbone 1H-15N peaks 
plus two pairs of unassigned side chain NH2 peaks 
KIBRA C2: distinctive phosphoinositide and Ca2+ binding 
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(Fig. 4). The Kd for C2(C771A)-PI(3)P binding was 
determined as a representative case using 13 
perturbed residues (SI Fig. 7); the average Kd was 1 
mM. After phosphoinositide titration, CaCl2 was 
titrated into the same NMR samples to establish 
whether Ca2+ ions influence C2-phosphoinositide 
interaction or vice versa; there was no further 
spectral change upon CaCl2 addition.  
Co-crystallization experiments involving 
C2(C771A) and varC2 with PI(4,5)P2 or PI(3,4,5)P3 
yielded crystals of C2(C771A) with bound PI(4,5)P2 
and PI(3,4,5)P3 in ProPlex HT-96 condition G1 
(PDB 6FJD and 6FJC, 2.6  and 2.9  resolution, 
respectively). Both PI(4,5)P2 and PI(3,4,5)P3 bound 
to monomer A of an anti-parallel C2(C771A) dimer 
with polar interactions between R776 (b7-b8 loop) 
and negatively charged oxygen atoms of 
phosphoinositide phosphates (Fig. 5). L678 (b2) and 
V729 (b5) sidechains and main chain of L666 (b1) 
and I677 (b2) interact with the phosphoinositide 
inositol/aliphatic chains. The C2(C771A)-PI(4,5)P2 
and C2(C771A)-PI(3,4,5)P3 crystal structure 
binding site is consistent with the phosphoinositide-
induced spectral changes in the 1H-15N HSQC 
titrations;  the backbone NH groups of L666, I677 
and L678, for example, showed the largest chemical 
shift changes. Phosphoinositide binding occurs with 
small changes in C2 structure e.g. a typical overall 
RMSD of 0.28  between unbound and 
phosphoinositide-bound structures. 
 Coarse-grained MD simulations were 
performed to further examine KIBRA C2 monomer 
and dimer association with phosphoinositides and 
membranes. In these simulations, which can predict 
the binding modes of peripheral proteins to model 
membrane (35, 36), the three experimentally 
observed forms of KIBRA C2 (monomer, anti-
parallel dimer, and parallel dimer, all without Ca2+) 
were displaced away from a pre-formed 
phosphoinositide-containing bilayer. In the primary 
(more frequent) binding mode observed with a C2 
monomer, C2 interaction with phosphoinositides 
involves mainly R661, K671, R772, R776 and R779 
(Fig. 6), slightly shifted from the crystal 
structure/NMR titration binding site. In a small 
number of simulations, the C2-phosphoinositide 
interaction involves mainly K667 and R776, 
coincident with the crystal structure/NMR titration 
binding site (Figs. 4 and 5). The parallel dimer 
(wtC2/2Z0U) shows two binding modes with one 
phosphoinositide often located close to the crystal 
structure/NMR titration binding site (Fig. 7). The 
anti-parallel dimer (C2(C771A)) exhibits a primary 
binding mode in which the main interactions with 
the membrane occur via one of the two C2 domains 
(Fig. 8). In this orientation, a phosphoinositide is 
observed near the crystal structure/NMR titration 
binding site. In all cases, KIBRA C2 domain binding 
to the bilayer causes a degree of phosphoinositide 
clustering around the domain. Phosphoinositides 
interact mainly with lysines and arginines that face 
the bilayer. 
 
Discussion 
KIBRA C2 structure 
We have elucidated structural and functional 
characteristics of four forms of KIBRA C2 domain: 
wild type, naturally occurring variant, and C771A 
mutants of wild type and variant. Variant KIBRA, 
involving two amino acid changes in the C2 domain 
(M734I, S735A), affects human cognitive 
performance and is in almost complete linkage 
disequilibrium (30) with a previously identified 
intronic SNP that affects cognition (15, 16). WtC2 
and varC2 adopt a type I topology C2 domain fold 
with slightly different dimerisation properties in 
solution (SI Fig. 1) indicating a possible effect of 
M734I/S735A residue differences on domain 
behaviour. The M734I substitution has previously 
been calculated to reduce C2 stability (30), although 
wtC2 and varC2 adopt very similar conformations in 
both crystal structures and in solution (SI Fig. 3 and 
SI Fig. 5).  
It has been shown previously that full length 
wild type KIBRA forms dimers in mammalian cells 
(20). Over-expression of Flag-tagged KIBRA in 
HEK293 cells, moreover, resulted in large KIBRA-
containing clusters (20). KIBRA also forms 
heterodimers with the two other WWC protein 
family members, WWC2 and WWC3 (10). Yeast 
two-hybrid mapping indicated that KIBRA 
dimerises in an anti-parallel orientation, with the C2 
domain and one or more regions N-terminal of C2 
required for this interaction (20). Whether or not 
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KIBRA can dimerise in mammalian cells via inter-
molecular disulfide bonding remains open to 
question. Since redox potentials, and therefore 
likelihood of intermolecular disulfide bonding, vary 
according to cell type, cell status and cell 
compartment, a mixture of non-covalent and 
covalent WWC protein dimerisation modes is 
possible in vivo. The degree of KIBRA dimerisation 
and/or oligomerisation in the cell could, for 
example, fine tune KIBRA function as a hub for 
multi-protein complex assembly. Different 
dimerisation tendencies of wtC2 and varC2 could 
then provide an indication of the molecular 
mechanism(s) underpinning the link between variant 
KIBRA C2 and improved cognition (30). Other 
components of the Hippo pathway are modulated by 
dimerisation; indeed, YAP2L and TAZ form 
disulphide-mediated dimers that are more stable and 
more oncogenic than the corresponding monomers 
(37). Finally, since oxidative stress can promote 
disulfide bond formation in cytoplasmic proteins 
(38), the extent of disulfide-mediated KIBRA 
dimerisation, and hence KIBRA function, could be 
regulated by oxidative stress. It is potentially 
relevant in this context that KIBRA-associated 
pathways can be redox-modulated (39) and that 
oxidative stress is a hallmark of AD (40).   
 
Calcium binding 
Any KIBRA C2-Ca2+ interaction is low affinity 
(Kd > 10 mM): we did not observe bound metal ions 
in any of our six C2 crystal structures, with or 
without crystal soaking with Ca2+ or other divalent 
metal ions, or bound phosphoinositide; and there is 
no bound Ca2+ in the previous wtC2 structure (PDB 
2Z0U). In NMR-monitored Ca2+ titrations, 
moreover, the C2(C771A) 1H-15N HSQC spectrum 
did not change significantly. Unlike KIBRA C2, 
most C2 domains bind Ca2+ with sub-mM affinity. 
For example, synaptotagmin I C2B domain has a 
Ca2+ affinity of about 500 µM (41), perforin C2 ~200 
µM (42), and rabphilin-3A  C2B domain has a 
particularly high Ca2+ affinity with Kd values of 7 
µM and 11 µM (43) explained by contributions from 
C2-flanking residues (44). Like KIBRA C2, 
however, some C2 domains show very weak or no 
residual calcium binding e.g. rat synaptotagmin 4 
C2A domain binds Ca2+ with a Kd around 10 mM, 
and rat synaptotagmin 4 C2B domain essentially 
cannot bind Ca2+, despite the lack of an obvious 
sequence reason (45). The very low Ca2+ affinity of 
KIBRA C2 could at least partly arise from sub-
optimal sequences for Ca2+ binding in CBR1 and 
CBR3 (SI Fig. 8).  
 
Phosphoinositide binding and membrane 
association 
C2 domains have been shown to bind 
phospholipids via the Ca2+ binding regions (31, 46), 
where the phospholipid contributes to the Ca2+ 
coordination sphere. C2 domains also bind 
phospholipids and phosphoinositides via a b3-b4 
lysine-rich cluster (31, 47, 48). Our XRC data 
involving C2(C771A), however, indicate that 
KIBRA C2 domain binds phosphoinositide in a 
novel way involving residues from strands b1, b2, 
and b8 (Fig. 5, PDB 6FJC, 6FJD). Given this 
unusual binding mode, we checked whether C2 
dimerisation and/or crystal packing hinders 
phosphoinositide binding at the previously identified 
C2-phosphoinositide binding sites: anti-parallel C2 
domain dimerisation with strands b7 and b8 forming 
the inter-monomer interface, as observed in our 
C2(C771A) crystal structures, obscures neither 
CBRs nor b3-b4 lysine-rich cluster. Similarly, 
phosphoinositide interaction at the lysine-rich 
cluster is not prevented by crystal packing: the 
cluster is not occluded by symmetry-related 
molecules. Hence steric factors do not explain why 
the previously observed phospholipid binding 
modes were not observed for KIBRA C2. 
Essentially the same phosphoinositide binding 
site was also observed in NMR titrations of two 
phosphoinositides, PI(3)P and PI(4,5)P2, with 
C2(C771A) (monomeric), and of PI(4,5)P2 with 
varC2 (parallel dimer in crystal structure, Fig. 2), 
although the binding is relatively low affinity. The 
NMR-observed binding involved residues in b5 as 
well as b1, b2, and b8 (Fig. 4). Hence the observed 
b1, b2, b5 and b8 phosphoinositide binding site 
persisted, irrespective of whether the particular 
version of KIBRA C2 is predominantly monomer, 
anti-parallel dimer, or parallel dimer.  
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Possible reasons why phosphoinositide 
interaction with KIBRA C2 does not occur at 
previously identified C2-phosphoinositide binding 
sites include the fact that KIBRA C2 does not 
conform to the consensus sequence of the b3-b4 
lysine-rich cluster (SI Fig. 9) and may not have 
sufficient positively charged residues in the vicinity 
to support phosphoinositide binding. The lack of a 
lysine-rich cluster may reflect the fact that KIBRA 
is not required to promote membrane fusion and 
hence does not need to induce membrane curvature 
(49). Also, clashes occur when C2(C771A) and 
PI(4,5)P2-bound rabphilin 3A structures are 
overlaid; the side chain of KIBRA residue E757, for 
example, lies between phosphates 4 and 5 of 
PI(4,5)P2, and apparently would repel these 
phosphate groups of the phosphoinositide; a 
glutamate occurs at this position in the C2 domains 
of all three WWC proteins, but an asparagine occurs 
here in seven of the eight other aligned C2 domains 
(SI Fig. 9). In addition, our observation that KIBRA 
C2 binds calcium very weakly, or perhaps not at all, 
with consequent lack of electrostatic bridging 
between KIBRA C2 negatively charged side chains 
and negatively charged phosphoinositides, helps to 
explain why phosphoinositide binding is not 
observed at the CBRs in KIBRA C2. Although the 
phosphoinositide head group is normally expected to 
be the key moiety, it is also worth considering 
whether the type of non-polar tail influences 
binding; we used diC4 forms of phosphoinositides 
for reasonable solubility whilst retaining an aliphatic 
tail. Previous C2 studies have used a range of 
phosphoinositides, including just the PI(4,5)P2 head 
group (50, 51), diC8 tails (49), and seemingly full 
length tails (47), all resulting in typical C2-
phosphoinositide binding sites. It seems unlikely 
therefore that phosphoinositide tail type is a 
significant factor in our observation of an unusual 
phosphoinositide binding site in KIBRA C2. 
MD simulations indicate that when associated 
with membranes, KIBRA C2 can bind to multiple 
phosphoinositides. As observed for other 
membrane-bound proteins (52), this results in 
clustering of phosphoinositide lipids around the 
protein, with phosphoinositides binding to lysines 
and arginines that face the membrane. Such 
phosphoinositide lipid clustering around KIBRA C2 
is expected to change the local lipid environment. 
This, together with the fact that in some simulations 
we observe secondary orientations of KIBRA C2 
relative to the membrane, could influence partner 
protein recruitment and consequently processes such 
as trafficking of receptors involved in learning and 
memory.  
In summary, experimental and simulation data 
indicate that KIBRA C2 is a non-classical C2 
domain that can associate with membranes in a 
distinctive side-on, Ca2+-independent manner. 
Further investigation is required to tease out the 
detailed functional significance of this unusual mode 
of membrane association, and consequently its 
implications for molecular mechanisms of learning 
and memory, organ size control, and major diseases.  
Finally, we caution that we have observed this 
interaction mode using an isolated C2 domain in 
vitro. Although we have identified several factors 
that explain the observed binding mode, in the cell it 
is possible that other factors such as protein binding 
partners and membrane composition/structure alter 
KIBRA C2-membrane association mode. 
 
Experimental procedures 
Cloning, protein expression and protein 
purification 
Sequences encoding residues 658-785 of wild 
type and variant (M734I, S735A) human KIBRA, 
and C771A mutants of these, were PCR-amplified 
and inserted into pQE30 (Qiagen). Unless otherwise 
stated, the forms of KIBRA C2 are abbreviated as 
follows: wild type C2 = wtC2, variant C2 = varC2, 
C771A mutant C2 = C2(C771A), variant C771A 
mutant C2 = varC2(C771A) (details in SI Table 1). 
The resulting proteins, with the sequence 
MRGSHHHHHHGS N-terminal to G658 of human 
KIBRA, were expressed using BL21(DE3) with 
IPTG induction and purified as described previously 
(53). 15N- and 15N/13C-labelled C2 domain samples 
for nuclear magnetic resonance (NMR) were 
produced by expression in M9 minimal medium 
supplemented with 1 g/L 15NH4Cl as the sole 
nitrogen source or 1 g/L 15NH4Cl and 2 g/L 13C 
glucose as the sole nitrogen and carbon sources, 
respectively. For NMR and analytical 
ultracentrifugation (AUC), C2 was exchanged into 
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10-50 mM MES, pH 6.5, with 50-150 mM NaCl. For 
crystallisation screens, C2 was exchanged into 10 
mM MES, pH 6.5, 75 mM NaCl. 
 
NMR  
NMR data for resonance assignment (SI Fig. 3) 
were acquired at 35 ¡C on a 600 MHz Varian Unity 
INOVA spectrometer with an ambient temperature 
probe at University of Bath, or on cryoprobe-
equipped 700 MHz Bruker or 800 MHz 
Varian/Agilent spectrometers at the MRC 
Biomedical NMR Centre, Mill Hill. Protein 
concentration used for 3D NMR experiments was in 
the range 0.5 mM to 0.8 mM. NMR data were 
processed using NMRPipe/NMRDraw (54) and 
analyzed using CCPN Analysis (55). Backbone 
chemical shifts for C2(C771A) and varC2(C771A) 
were deposited in BMRB, accession numbers 27429 
and 27430, respectively. Talos (34) was used to 
predict C2 domain secondary structure from the 
assigned NMR chemical shifts. For comparison, 
secondary structure was predicted from crystal 
structures by using Sparta (33) to convert the 
coordinates to chemical shifts, and then using those 
to predict secondary structure. 
Numerous 1H-15N HSQC-monitored titrations 
of C2(C771A), and one of wtC2, with CaCl2 were 
conducted, including attempts to produce NMR 
samples that were initially calcium-free which 
involved buffer solutions made with commercial 
calcium-free water and treatment with EGTA. 
Typical initial sample conditions for these 
experiments were 50 mM MES, pH 6.5, 50 mM 
NaCl, and 10 mM MES pH 6.5, 150 mM NaCl, 
sometimes with EGTA (1 mM or 2 mM) as an 
additional measure to try to ensure that C2 was not 
Ca2+-bound to begin with. Final CaCl2 
concentrations in some of these titrations exceeded 
15 mM, in one case reaching 76 mM. 
Titrations of C2(C771A) with 
phosphatidylinositol 3-phosphate (PI(3)P) and 
phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) 
were monitored via 1H-15N HSQC spectra recorded 
at Mill Hill (700 MHz cryoprobe system), and 
titration of varC2 with PI(4,5)P2 was monitored via 
1H-15N HSQC spectra recorded in-house (600 MHz 
ambient temperature probe). Protein concentration 
used for these titrations was in the range 0.3 mM to 
0.5 mM. DiC4 versions of phosphoinositides 
(Echelon Biosciences) were used in these NMR 
experiments and in X-ray crystallography (XRC) 
(described below). The molar ratio of C2 to diC4-
phosphoinositide at each titration point was 1:0, 
1:0.25, 1:0.50, 1:0.75, 1:1 and 1:1.5 
(phosphoinositide cost prohibited higher 
phosphoinositide levels); a 1H-15N-HSQC spectrum 
was recorded at each titration point. CaCl2 was then 
titrated into the same NMR sample with ratios of C2 
to CaCl2 of 1:0.25, 1:0.50, 1:0.75, and 1:1; a 1H-15N-
HSQC spectrum was recorded after each CaCl2 
addition. 1H-15N chemical shift changes are reported 
as Ddav (ppm), where Ddav (ppm) = [(DdH2 + 
DdN
2(gN/gH))/2]0.5 (56). 
 
Analytical ultracentrifugation (AUC) 
Sedimentation velocity scans were recorded for 
four (varC2) or five (wtC2, C2(C771A), 
varC2(C771A)) concentrations of each construct; 
concentrations are listed in each panel of SI Fig. 1. 
All experiments were performed at 50000 rpm, 
using a Beckman XL-I analytical ultracentrifuge 
with an An-50Ti rotor. Data were recorded using the 
absorbance (at 280 nm) and interference optical 
detection systems. The density and viscosity of the 
buffers were measured using a DMA 5000M 
densitometer equipped with a Lovis 200ME 
viscometer module. The partial specific volume for 
each protein was calculated using Sednterp from the 
amino acid sequence. Data were processed using 
SEDFIT (57), fitting to the c(s) model (SI Table 2).  
 
X-ray crystallography 
Crystallization was performed using ProPlex 
and JCSG+ screens (Molecular Dimensions), 
utilizing the hanging drop vapour diffusion method 
at 18¡C. VarC2 crystallised in 0.15 M (NH4)2SO4 0.1 
M MES pH 6.0, 15% w/v PEG 4000, C2(C771A) 
(no ligand) crystallised in 0.1 M Na HEPES pH 7.5, 
0.8 M NaH2PO4, 0.8 M KH2PO4, and for the lipid-
bound studies, the NMR samples containing ligand 
were crystallised in 0.1 M Tris pH8.0, 1.5 M 
(NH4)2SO4. Glycerol was used as a cryoprotectant at 
25% v/v for all but the C2(C771A) (no ligand) 
crystals where 5% was sufficient. Diffraction data 
were collected using a Rigaku MicroMax 007HF 
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with a Saturn 944+ CCD detector. Data were 
processed with D*Trek or HKL-2000 (58). 
Molecular replacement was carried out with 
BALBES (59), and the model refined using Coot 
(60) and Phenix (61). The resultant structures were 
evaluated using MolProbity (62, 63). Data collection 
and processing statistics are given in S1 Table 4. 
 
Coarse-grained molecular dynamics (CG-MD) 
simulations 
CG-MD simulations were performed using the 
Martini 2.1 force field (64, 65) and GROMACS 
(66). In the CG-MD simulations the protein (in 
monomeric and dimeric forms) was displaced away 
from a preformed bilayer. Protein orientation 
relative to the bilayer was different at the beginning 
of each repeat simulation. 25 repeat simulations of 2 
µs each were conducted. The bilayer consisted of 
POPC (~73%), POPS (~20%), PI(4,5)P2 (~5%) and 
phosphatidylinositol 3,4,5 trisphosphate 
(PI(3,4,5)P3) (~2%). All systems were energy-
minimized and subsequently equilibrated (for 500 
ns) with the protein backbone particle restrained. For 
the production simulation the time step was 20 fs, 
the pressure was 1 bar and the temperature was 323 
K. Berendsen's algorithm (67) was used to control 
the pressure and the temperature. An elastic network 
model (ENM) was applied to all backbone particles 
with a cut-off distance of 0.7 nm (68). The LINCS 
algorithm was used to constrain bond lengths (69) 
and the Lennard-Jones interactions were shifted to 
zero between 0.9 nm and 1.2 nm. Coulombic 
interactions were shifted to zero between 0 and 1.2 
nm.  
 
Atomistic molecular dynamics (AT-MD) 
simulations 
AT-MD simulations were run at 310 K using 
GROMACS and two different force fields: the 
GROMOS96 43a1 force field (70) was used with 
SPC water molecules and the OPLS-AA force field 
with TIP4P water molecules. The velocity rescaling 
method (71) was used to control the temperature and 
the Parrinello-Rahman barostat (72) was used for 
pressure control. Isotropic pressure coupling was 
used. Bond lengths were constrained to equilibrium 
lengths using the LINCS method and the particle 
mesh Ewald (PME) method was used to model the 
electrostatic interactions. The time step was 2 fs. 
WtC2, varC2, and varC2(C771A) structures were 
used for these simulations. Two simulations of 100 
ns and one simulation of 300 ns were performed for 
each force field. We also performed Simulations 
were also conducted with monomeric KIBRA C2 
domain in solution in which eight calcium ions were 
randomly added. Eight repeat 100 ns simulations 
were performed, each starting from different initial 
configurations, using the OPLS-AA force field with 
TIP4P water molecules. 
!
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Figure legends 
Figure 1. Schematic structure of human KIBRA protein showing locations of motifs and domains. The NLS 
and coiled coil regions are predicted rather than experimentally demonstrated. 
 
Figure 2. Crystal structures of variant and mutant (C771A) KIBRA C2. (A) VarC2 parallel dimer (PDB 6FD0). 
(B) C2(C771A) anti-parallel dimer (PDB 6FB4). Termini, b-strands, a-helices and residue 771 are labelled. 
In (A), the C771 label corresponds to the position of the inter-monomer disulfide bond which mediates 
parallel dimer formation in the wtC2 and varC2 crystal structures. 
 
Figure 3. MD simulation of KIBRA C2 dimer conformation in solution. RMSD for wtC2 (A), varC2 (B), and 
varC2(C771A) (C) with RMSD for the monomers in blue and red, and for the dimer in black is shown for one 
of the simulations of each system. Final structures from the three repeat simulations for each system are 
also shown, with one monomer superimposed, in blue, red, and orange, with the corresponding crystal 
structure in grey. 
 
Figure 4. C2(C771A)-PI(3)P interaction monitored by NMR. (A) Overlay of C2(C771A) 1H-15N HSQC spectra 
as a function of increasing PI(3)P concentration. Perturbed backbone NH peaks are labelled, and the two 
perturbed but unassigned side chain NH2 peak pairs are connected by dashed lines and denoted as 
“scNH2”. The insets highlight the chemical shift changes of backbone NH peaks of I677 (strand b2) and 
W731 (b5), and of L678 (b2), I679 (b2) and R776 (b7-b8 loop). Peak colours and corresponding 
C2(C771A):PI(3)P ratios are as follows: red 1:0, pink 1:0.25, green 1:0.5, cyan 1:0.75, purple 1:1, black 1:1.5. 
(B) Perturbed residues mapped onto a ribbon representation of C2(C771A). Yellow represents residues 
with Ddav (ppm) ≤ 0.01, orange 0.01-0.03, red > 0.03, where Ddav (ppm) = [(DdH
2 + DdN2(gN/gH))/2]0.5. The 
secondary structure elements (b-strands and a-helices) are labelled. Also, for ease of comparison with 
other C2 domains, the location of canonical calcium binding regions (CBR1, CBR2 and CBR3) is indicated. 
 
Figure 5. X-ray diffraction structure of the C2(C771A)-PI(3,4,5)P3 complex. Three views of the complex 
(PDB 6FJC) in which rotation of view (A) about the vertical axis through approximately 90¡ gives view (B). 
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PI(3,4,5)P3 binds to chain A of an anti-parallel C2(C771A) dimer, as does PI(4,5)P2. (C) A closer view of the 
C2(C771A)-PI(3,4,5)P3 interaction in the same orientation as (A), with electron density obtained in a 
simulated annealing omit map around the PI(3,4,5)P3 binding site shown in blue mesh, contoured at 1.1s. 
PI(3,4,5)P3 is shown mainly in magenta. Some of the C2 residues that interact with PI(3,4,5)P3 are shown 
(hydrophobic residues in yellow, polar residues in cyan, and positively charged residues in blue), including 
the side chains of L678, Q681, N727 and R776, and backbone of L666 and I677. Oxygen and nitrogen atoms 
are shown in red and dark blue, respectively. 
 
Figure 6. Coarse-grained MD simulation of KIBRA C2 monomer association with membrane. (A) Coarse-
grained simulation set up. Snapshots are shown from one of the simulations at 0 μs, ~0.2 μs and 2 μs.  
KIBRA C2 domain is shown in grey, lipid phosphate atoms in orange and phosphoinositide lipids in green. 
(B) A snapshot of one of the simulations showing the preferred orientation of the C2 domain relative to 
the bilayer. (C) Alignment of C2 domain from the simulations (grey) with PI(3,4,5)P3-bound C2 crystal 
structure (blue). The phosphoinositides bound to C2 in the simulations are also shown. Oxygen atoms on 
lipids are shown in red, hydrogen atoms in white, and carbon atoms in cyan. 
 
Figure 7. Coarse-grained MD simulation of KIBRA C2 parallel dimer association with membrane. (A) 
Primary and (B) secondary binding mode of the KIBRA C2 parallel dimer from simulation. KIBRA C2 domain 
is shown in grey, lipid phosphate atoms in orange and phosphoinositide lipids in green. Residues K667 and 
R776 are shown in blue. (C) and (D) Alignment of C2 domain from the simulations (grey) with the 
PI(3,4,5)P3-bound C2 crystal structure (blue). The phosphoinositides bound to C2 in the simulations are 
also shown. The phosphoinositide molecule that is close to the phosphoinositide binding site observed by 
XRC and NMR is shown in green. Oxygen atoms on lipids are shown in red, hydrogen atoms in white, and 
carbon atoms in cyan.    
 
Figure 8. Coarse-grained MD simulation of KIBRA C2 anti-parallel dimer association with membrane. (A) 
Primary orientation of the varC2(C771A) anti-parallel dimer relative to the bilayer. The C2 dimer is shown 
in grey and lipid phosphate atoms in orange. (B) Phosphoinositide binding sites on KIBRA C2 resulting from 
simulation. The residues in each site are shown in a different color. (C) The varC2(C771A) crystal structure 
is shown in the same orientation as in (A) and (B). Residues K667 and R776 that interact with the 
phosphoinositide analogue are shown as yellow spheres. Oxygen atoms on lipids are shown in red, 
hydrogen atoms in white, and carbon atoms in cyan. 
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